Bull & Bear

Figures converted from Swiss francs at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Bull and Bear

Verdict: Lean Long, Wait For Confirmation — the operating engine is genuinely compounding and the stock is de-rated to roughly 20x from a 30x-plus history, but the re-rating the bull needs hinges on a variable neither advocate controls: the Swiss franc. Both sides agree on the facts. In FY2025/26 local-currency sales rose 5.9% to $4,549m and normalized EBITA rose 17.3% to $1,023m [3], and normalized continuing EPS rose 16.0% in local currency yet stayed flat in francs at $13.15 [1] — while the reported number the market actually capitalizes, EPS including discontinued operations, fell to $9.12 [2].

The debate is not about whether the business is good; it is about whether the reported-earnings drought is an FX optical illusion that reverses (Bull) or a structural drag that has held for three straight years and that management itself guides will continue into FY2027 (Bear). That single tension — will reported franc EPS actually inflect positive — decides the multiple, and its trigger sits outside the report's evidence. The evidence that would settle it is one clean FY2026/27 print: reported franc EPS growing while Wholesale local-currency growth holds its high-single/double-digit pace. Until that arrives, the operating quality earns a long lean, not a full commitment.

Bull Case

Bull's three sharpest points are the FX-masked earnings, the best product cycle in company history taking channel share, and peer-leading cash-backed returns at a de-rated multiple. Point 1: reported diluted EPS looks stalled, but underneath local-currency sales rose 5.9% to $4,549m and normalized EBITA rose 17.3% to $1,023m [3], with a strong franc alone cutting reported sales by $279m, or 6.1 points of growth [4]; US sales, where the money is, grew 9.1% in local currency [5]. Point 2: the Phonak Infinio / Sphere platform sold over 1.5 million units in its first year — the most successful launch in company history [6] — pushing US Veterans Affairs share to a five-year high [7] and lifting Wholesale sales 9.5% in local currency to $2,349m [8]. Point 3: gross margin was 73.7% [9], the core Hearing Instruments segment earned a 23.7% normalized EBITA margin [10], group ROCE was 19.0% and operating free cash flow $655m [11], against a management track record of 18-20% ROCE through the cycle [12]. Dropped: the fortress-balance-sheet-plus-un-fired-buyback point — a real quality feature, but optionality rather than a thesis driver.

Sources: local-currency sales and normalized EBITA [3]; Wholesale sales [8]; gross margin [9]; operating free cash flow and ROCE [11]; Hearing Instruments segment margin [10]; Infinio launch [6].

Bull target: price target $326, via ~24x a blended forward normalized EPS of ~$13.5 — a partial re-rating from ~20x toward the quality-justified mid-20s as reported franc EPS inflects positive — over a 12-18 month horizon (the FY2026/27 reporting cycle). Bull's primary trigger is the FY2026/27 prints showing reported franc EPS growth turning positive as the FX drag fades and the Consumer Hearing loss drops out of comparatives, validating the 5-8% sales / 7-10% core EBIT guide [13]; the durable thesis variable it tests is the $7.4 billion revenue ambition by FY2030/31 [14]. Bull's own disconfirming signal: Wholesale local-currency growth decelerating back toward low single digits, or the Hearing Instruments normalized EBITA margin breaking below its ~20% through-cycle floor.

Bear Case

Bear's three sharpest points are the grinding-down reported EPS, cash conversion flattered by a payables stretch, and a narrow product-cycle moat that is already reversing. Point 1: reported franc EPS has fallen three years running — from a $11.61 diluted peak in the year to March 2023 [15] to $9.12 in FY2026 [2] — because a structurally strong franc erases local-currency growth before it reaches the bottom line, with FX cutting FY2026 sales by $279m [4]. Point 3 (cash): operating free cash flow fell 10.8% to $655m [11] while net working capital ballooned to $316m from $145m [2], as a deliberate supplier-payment stretch (Days Payables Outstanding ~90 to 60) reversed and trade payables swung from a source to a use of cash. Point 4 (moat): Cochlear Implants sales fell 11.1% in local currency to $318m against an ageing 2021 processor [16], while Sonova abandoned the fast-growing low end by divesting Consumer Hearing, booked as a discontinued operation, at a $134m loss [17], and a debt-funded retail roll-up has pushed goodwill to $2,882m, or 87% of equity [18]. Dropped: the "record margin is a non-GAAP construct" point — legitimate, but the margin-compression fact (reported EBIT margin 18.7% vs the FY2021 peak) survives inside the moat point.

Sources: reported earnings per share [2]; operating free cash flow [11]; Cochlear Implants sales [16]; discontinued-operations loss [17]; peak diluted earnings per share [15]; goodwill [18].

Bear downside: target $203 (~21% below the ~$258 close), via multiple compression to the peer median (~16x) on FY2027 consensus normalized EPS of ~$12.8, cross-checked against the $207 the stock actually printed on the 23 March 2026 divestment news, over the same 12-18 month horizon. Bear's primary trigger is FY2026/27 results showing Wholesale local-currency growth decelerating from its Infinio-driven pace back toward low single digits while reported franc EPS again fails to grow — refuting the share-gain re-rating; the durable variable it tests is whether Sphere/Infinio share gains can re-accelerate earnings at all. Bear's cover signal: a year in which reported franc EPS grows high-single-digits with Wholesale LC holding double digits and Cochlear Implants stabilizing.

The Real Debate

The two advocates argue over the same three facts, not different ones: the flat-in-francs, up-16%-in-local-currency EPS [1] [2]; the Wholesale-up-9.5% [8] versus Cochlear-Implants-down-11.1% [16] split; and the record 22.5% normalized margin sitting above an 18.7% reported EBIT margin with operating FCF down 10.8% [11].

Sources: normalized continuing earnings per share [1]; reported earnings per share [2]; exchange-rate impact on sales [4]; Wholesale sales [8]; operating free cash flow [11]; Cochlear Implants sales [16].

Verdict

Lean Long, Wait For Confirmation. Bull carries more weight because the case rests on facts you can verify today — local-currency sales up 5.9%, normalized EBITA up 17.3%, the most successful product launch in company history, 73.7% gross margins and 19% ROCE — whereas Bear's decisive claim rests on a franc forecast no one in this report can make. The single most important tension is the first: whether the reported-EPS decline is optical or real. Bear could still be right, and it is not a weak case: the franc has erased local-currency growth for three consecutive years, management itself guides a further 3-4 point drag into FY2027, and a stock at ~20x with a Hold-tilting-sell consensus is not obviously cheap if reported EPS keeps sliding — the bull's own primary catalyst, reported francs turning positive, may simply not fire on schedule. That is why this is a lean and not a commitment: the durable thesis (share-driven compounding at a de-rated multiple) is intact and would only break if Wholesale local-currency growth decelerates toward low single digits or the Hearing Instruments margin cracks its ~20% floor — the real thesis-breaker — while the near-term evidence marker is narrower and FX-contingent: reported franc EPS finally growing while Wholesale LC holds its pace. Buy the confirmation, not the forecast; upgrade to Lean Long when a FY2026/27 print shows reported EPS inflecting with Wholesale momentum intact, and step aside toward Avoid if the Wholesale cadence rolls over first.